
    
      This is a randomized, double-blind, placebo-controlled study to assess the efficacy and
      safety of NYX-2925 in subjects with neuropathic pain associated with diabetic peripheral
      neuropathy.

      The study will be a 13- to 16-week study, including a 1- to 4-week Screening Period, followed
      by a 12- week double-blind, randomized, placebo-controlled Treatment Period.
    
  